A pharmaceutical company approached us with their own assay developed on our DISCOVERY platform. We moved quickly to establish a Master Collaboration Agreement and tested their assay only to find out that it failed requirements for a companion diagnostic. We pivoted to develop both the formulation locked assay and IUO and started clinical trials within record time, keeping their programs on track.
Since the global launch of the VENTANA PD-L1 (SP263) Assay as a companion test, it has become the #3 selling assay in our portfolio of over 250 antibodies, and this collaboration has grown into a franchise with multiple indications. We now are their strategic partner for IHC and remain engaged with them on multiple early and late stage development programs.
Together, we’ve enabled significant access to personalized therapy for cancer patients.